Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer

Part of paid clinical trials in Beverly Hills, California.

Sponsor
Jounce Therapeutics, Inc.
Study ID
NCT03989362
Phase
PHASE2
Status
Completed

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Vopratelimab — DRUG
    Specified dose on specified days
  • Ipilimumab — DRUG
    Specified dose on specified days

Study Details

JTX-2011-201 is a Phase 2, open label clinical study of vopratelimab (JTX-2011) and ipilimumab in adult subjects with non-small cell lung cancer (NSCLC) or urothelial cancer to evaluate safety and efficacy.

Key Dates

Start date
Jun 6, 2019
Status verified
Apr 2022
Primary completion
Mar 15, 2022
Completion
Mar 15, 2022

Study Design

Enrollment
61 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: LM1
    Phase 2 study of vopratelimab by intravenous (IV) infusion administered in combination with ipilimumab by IV infusion in NSCLC
  • Experimental: LT1
    Phase 2 study of vopratelimab by IV infusion administered in combination with ipilimumab by IV infusion in NSCLC
  • Experimental: UM1
    Phase 2 study of vopratelimab by IV infusion administered in combination with ipilimumab by IV infusion in urothelial cancer
  • Experimental: UT1
    Phase 2 study of vopratelimab by IV infusion administered in combination with ipilimumab by IV infusion in urothelial cancer
  • Experimental: LM2
    Phase 2 study of vopratelimab by intravenous (IV) infusion in administered in sequence with ipilimumab by IV infusion in NSCLC
  • Experimental: LT2
    Phase 2 study of vopratelimab by intravenous (IV) infusion in administered in sequence with ipilimumab by IV infusion in NSCLC
  • Experimental: UM2
    Phase 2 study of vopratelimab by intravenous (IV) infusion in administered in sequence with ipilimumab by IV infusion in urothelial cancer
  • Experimental: UT2
    Phase 2 study of vopratelimab by intravenous (IV) infusion in administered in sequence with ipilimumab by IV infusion in urothelial cancer

Primary Outcome Measure

% subjects with overall response (OR) [ Time Frame: 34 months ]

Locations (18)

FacilityCityStateZIPSite coordinators
Beverly Hills Cancer CenterBeverly HillsCalifornia90211-
University of Southern California Medical CenterLos AngelesCalifornia90033-
Christiana Care Health ServicesNewarkDelaware19713-
Florida Cancer Specialists Sarasota CattlemenSarasotaFlorida34232-
University of Maryland - Marlene and Stewart Greenebaum Cancer CenterBaltimoreMaryland21201-
Massachusetts General HospitalBostonMassachusetts02114-
Washington University School of MedicineSt LouisMissouri63110-
The Valley HospitalRidgewoodNew Jersey07450-
Weill Cornell Medical CollegeNew YorkNew York10065-
University of RochesterRochesterNew York14642-
Southeastern Medical Oncology CenterClintonNorth Carolina28328-
Cleveland Clinic FoundationClevelandOhio44195-
Allegheny Health Network Research InstitutePittsburghPennsylvania15212-
Lifespan Cancer InstituteProvidenceRhode Island02903-
Vanderbilt University Medical CenterNashvilleTennessee37232-
University of Texas MD Anderson Cancer CenterHoustonTexas77030-
University of The Texas Health Science Center at San AntonioSan AntonioTexas78229-
University of Virginia Health SystemCharlottesvilleVirginia22908-

Find similar trials in Beverly Hills, CA

By research site
Beverly Hills Cancer Center· Beverly Hills, CAUniversity of Southern California Medical Center· Los Angeles, CAChristiana Care Health Services· Newark, DEFlorida Cancer Specialists Sarasota Cattlemen· Sarasota, FLUniversity of Maryland - Marlene and Stewart Greenebaum Cancer Center· Baltimore, MDMassachusetts General Hospital· Boston, MA

Related Studies